Abstract. 2A⌬30 is a live dengue-4 virus vaccine candidate with a 30-nucleotide deletion in its 3Ј-untranslated region. To assess the transmissibility of 2A⌬30 by mosquitoes, we compared its in vivo replication in mosquitoes with that of its wild type DEN-4 parent. Both the vaccine candidate and wild type virus were equally able to infect the mosquito Toxorhynchites splendens after intrathoracic inoculation. Relative to its wild type parent, 2A⌬30 was slightly restricted in its ability to infect the midgut of Aedes aegypti mosquitoes fed on an artificial blood meal and was even more restricted in its ability to disseminate from the midgut to the salivary glands. Thus, the 30-nucleotide deletion rendered the vaccine candidate more sensitive than its wild type parent to the mosquito midgut escape barrier. Most significantly, 2A⌬30 was not transmitted to 352 Ae. albopictus mosquitoes fed on 10 vaccinees, all of whom were infected with the vaccine candidate.
INTRODUCTION
Dengue virus is the etiologic agent of the mosquito-borne disease dengue fever, as well as its more severe variants dengue hemorrhagic fever (DHF) and dengue shock syndrome (DSS). 1 Dengue virus is a single-stranded, positivesense RNA virus in the genus Flavivirus, family Flaviviridae. 1 There are four serotypes of dengue virus (DEN-1, DEN-2, DEN-3, and DEN-4), each capable of causing disease in humans. Infection with one serotype leads to a longlived homologous immunity and a transient heterotypic immunity. 2 DHF/DSS usually occurs during secondary infection. 3, 4 Dengue virus is a growing threat to the health of people living in tropical and semitropical areas, 5, 6 with an estimated 50-100 million cases of dengue fever occurring annually. 7 Antiviral therapy is not available against dengue virus. Prevention of dengue currently depends entirely on vector control, which can successfully reduce transmission, but requires an organized and sustained effort. Vaccination promises to be an essential tool for limiting the spread of dengue virus. At present, a licensed dengue virus vaccine is not available. Because of the increased likelihood of DHF/DSS during a secondary infection, a vaccine against dengue virus must generate lasting immunity to each of the four serotypes simultaneously. Tetravalent live attenuated dengue vaccine candidates are being developed that should induce strong immune responses to all four serotypes with minimal reactogenicity. The candidate should not be transmissible from humans to mosquitoes to prevent both the introduction of dengue virus into new environments and the loss of the attenuation phenotype that can result from sustained transmission of live virus vaccines. 8, 9 Recombinant DNA technology has greatly facilitated the development of live attenuated vaccines for dengue and other flaviviruses. [10] [11] [12] [13] [14] [15] [16] . The dengue vaccine candidate 2A⌬30 was derived from a cDNA clone of DEN-4 and contains a 30-nucleotide deletion in the 3Ј-untranslated region of the * Equal contribution by the first two authors.
virus. 17 It has recently been reported (in the current issue) that 2A⌬30 is attenuated and immunogenic in adult humans. 18 . 2A⌬30 not only shows promise as a vaccine against DEN-4, but it also offers a genetic ''backbone'' for the creation of chimeric viruses containing the structural genes (C, prM and E) of DEN-1, DEN-2, and DEN-3. 18, 19 Thus, 2A⌬30 could provide the genetic foundation for a tetravalent dengue vaccine.
Here we report the results of a study assessing the potential transmissibility of 2A⌬30 by mosquitoes. The ability of 2A⌬30 and its wild type DEN-4 parent virus to grow on simian and mosquito cells, to infect non-haematophagous mosquitoes following intrathoracic inoculation, and to infect Aedes aegypti mosquitoes fed via an artificial blood meal were compared. Additionally, the transmissibility of 2A⌬30 from infected human vaccinees to Ae. albopictus mosquitoes was examined by allowing mosquitoes to feed on the vaccinees during the time of peak viremia.
MATERIALS AND METHODS
Viruses and cells. DEN-4 strain 814669 was used as the wild type virus (wtDEN-4) in this study; 2A⌬30 is a vaccine candidate derived from the 2A cDNA clone of DEN-4 strain 814669 and contains a 30-nucleotide deletion, previously designated 3Јd 172-143, in the 3Ј-untranslated region. 17, 18 Virus stocks of wtDEN-4 and 2A⌬30 were prepared by amplification in simian Vero cell monolayer cultures, clarified by centrifugation, and stored at Ϫ70ЊC. 18 Vero cells were maintained as cell monolayer cultures in VP-SFM medium (Life Technologies, Inc. Grand Island, NY) supplemented with 2 mM glutamine (Life Technologies, Inc.) and 0.05 mg/ ml of gentamicin (Life Technologies, Inc.) and held at 37ЊC in an atmosphere of 5% CO 2 . Mosquito (Ae. albopictus) C6/ 36 cell monolayer cultures were maintained in minimal essential medium with 25 mM HEPES buffer (Life Technologies, Inc.) supplemented with 10% fetal bovine serum (Summit Biotechnologies, Fort Collins, CO), 0.05 mg/ml of gentamicin, 2 mM glutamine, and 2 mM non-essential amino acids (Life Technologies, Inc.) and held at 32ЊC in an atmosphere of 5% CO 2 .
Multicycle replication in Vero and C6/36 cells. 2A⌬30 and wtDEN-4 were each inoculated at a multiplicity of infection of 0.1 onto triplicate confluent monolayers of either Vero or C6/36 cells in 75-mm flasks. Cells were then incubated for 1 hr at the temperatures described above, washed twice in 10 ml of appropriate media, after which an additional 20 ml of media was added. After 5 min, 1 ml of media was removed from each flask, aliquoted into three vials, flash-frozen on dry ice, and stored at Ϫ70ЊC. Each flask was replenished with 1 ml of media, and additional specimens were obtained at 24-hr intervals over the next six days. The viral titer at each time point was determined by plaque titration as follows. Confluent Vero cell monolayers on 24-well plates were inoculated in duplicate with serial 10-fold dilutions of supernatant fluid, incubated at 35ЊC in an atmosphere of 5% CO 2 for 2 hr, and overlaid with 0.8% methylcellulose in OptiMEM (Life Technologies, Inc.) supplemented with 2% fetal bovine serum, 2 mM glutamine, and 0.05 mg/ml of gentamicin. Plates were subsequently incubated at the conditions described above for five days. Plates were immunostained as previously described. 18 Mosquitoes. Aedes aegypti and Ae. albopictus mosquitoes are the primary vectors of dengue virus. 6 Both species were reared at 26ЊC at a relative humidity of 80% with a 16-hr daylight cycle. Adults were allowed continuous access to a cotton pad soaked in a 10% sucrose solution. Toxorhynchites splendens mosquitoes were reared at 24ЊC and a relative humidity of 75% with a 12-hr daylight cycle. Larvae and pupae were fed on appropriately sized Aedes larvae; adults were allowed continuous access to a cotton pad soaked in a 10% sucrose solution.
Oral infection of mosquitoes. Five to ten day-old female Ae. aegypti that had been deprived of a sugar source for 48 hr were fed a blood meal consisting of equal volumes of washed human red blood cells, 10% sucrose solution, and dengue virus suspension. The infected blood meal was prepared immediately prior to feeding and offered to mosquitoes in a water-jacketed feeder covered in stretched Parafilm (American National Can, Chicago, IL) and preheated to 38ЊC. 20 Mosquitoes that took a full blood meal within 45 min were transferred to a new container by aspirator and maintained as described above. After 21 days, mosquitoes were stored at Ϫ20ЊC until dissection.
Detection of viral antigen in body and head tissues by immunofluorescence assay (IFA). The head and midgut were removed from each mosquito and squashes were prepared on glass slides as previously described. 21 The remaining carcass was frozen at Ϫ20ЊC. Slides were fixed in acetone for 20 min, and placed at 4ЊC until processed by IFA. The primary antibody, hyperimmune mouse ascites fluid specific for DEN-4, was diluted 1:100 in phosphate-buffered saline (PBS)-Tween 20 (0.05%). Slides were incubated at 37ЊC in a humid chamber for 30 min, and subsequently rinsed in PBS-Tween 20. The secondary antibody, fluorescein isothiocyanate conjugated goat anti-mouse IgG (Kirkegaard and Perry Laboratories, Gaithersburg, MD), was diluted 1:200 in PBS-Tween 20 with 0.002% Evan's blue. Slides were viewed on an Olympus (Melville, NY) BX60 microscope. The oral infectious dose required to infect 50% of mosquitoes (OID 50 ) was determined by the method of Reed and Muench. 22 Two OID 50 values were calculated for each virus: the OID 50 required to produce an infection in the midgut, with or without dissemination to the head, and the OID 50 required to produce disseminated infection.
Intrathoracic inoculation. The large, non-haematophagous mosquito T. splendens is a sensitive host for determining the infectivity of dengue virus. 23 One to ten day-old adult T. splendens of both sexes were immobilized by immersion of their container in an icewater bath and inoculated intrathoracically with a 0.22-l dose of virus using a Harvard Apparatus microinjector (Medical Systems Corp., Greenvale NY) and a calibrated glass needle (technique is a modification of the method previously described 24 ). To determine the 50% mosquito infectious dose (MID 50 ) of 2A⌬30 and wt DEN-4, mosquitoes were inoculated with serial 10-fold dilutions of virus in PBS. To detect the occurrence and temporal pattern of viremia in human vaccinees, groups of mosquitoes were inoculated with undiluted serum obtained from individual vaccinees on day 9. Control mosquitoes were inoculated with PBS. Inoculated mosquitoes were incubated under the conditions described above for 14 days and afterward stored frozen at Ϫ20ЊC, since Watts and others 23 previously observed that 14 days is ample time for the detection of specific fluorescence in Toxorhynchites infected intrathoracically with dengue virus. To assay for the presence of virus, head squashes were prepared for each mosquito and IFA was conducted as described above, except that mouse monoclonal antibody 4G2 (diluted 1:100) was used as the primary antibody. This monoclonal antibody was derived from hybridoma HB112 (American Type Culture Collection, Manassas, VA), and was specific for flavivirus group-specific antigens.
Aedes albopictus fed on human volunteers vaccinated with 2A⌬30. The safety and immunogenicity of 2A⌬30 was tested in a Phase 1 clinical trial, as described. 18 Informed consent was obtained from all human adult participants and the project was approved by The Joint Committee on Clinical Investigation of the Johns Hopkins University School of Medicine. Following immunization with vaccine candidate 2A⌬30, serum for virus titration was collected from each of 10 volunteers on days 2, 4, and 6 through 14. Serum was assayed for presence and titer of virus using two different methods: 1) in vitro by both direct plaque titration and blind passage on a Vero cell monolayer followed by plaque titration (as previously described 18 ) or 2) in vivo by inoculation of T. splendens as described above.
Results from plaque titration indicated that days 7, 8, and 9 post-infection represent a period of detectable viremia. 18 To test the potential for transmission of 2A⌬30, Ae. albopictus mosquitoes were fed on vaccinated volunteers on days 7, 8, and 9 post-vaccination. We chose to use Ae. albopictus for this transmission study because it is the only locally abundant dengue vector in Baltimore, Maryland, the area in which the vaccine trials were conducted. Information about the likelihood of the transmission of the vaccine to this vector is helpful in assessing risks of the potential transmissibility of this vaccine candidate if future studies are conducted in open communities. Ten to fifteen 5-7-day-old female Ae. albopictus that were held in an individual pint container with a mesh lid were placed under the forearm of each vaccinee and the mosquitoes were allowed to feed for 10 min. Unfed and partially fed mosquitoes were removed from the containers and destroyed; fully engorged mosquitoes were housed under the same conditions described above for Ae. aegypti. Twenty-one days after feeding, mosquitoes were frozen and head and midgut tissues were examined by IFA to detect the presence of dengue virus antigens. Aedes albopictus fed on a blood meal lacking dengue virus were used as negative controls for the IFA. Aedes albopictus infected with wtDEN-4 were used as positive controls.
Statistical analysis. All analyses were conducted using Statview software (SAS Institutes, Inc., Cary, NC).
RESULTS

Replication in vitro.
The kinetics and magnitude of replication of 2A⌬30 and wtDEN-4 were compared in both Vero and C6/36 cells (Figure 1) . The overall pattern of replication of the two viruses was similar in the two cell lines. The peak titers of the two viruses were not significantly different in Vero cells (wtDEN-4 and 2A⌬30 on day 6; unpaired t-test; degrees of freedom [df] ϭ 4, P ϭ 0.7), but the peak titer of wtDEN-4 in C6/36 cells was significantly higher than that of 2A⌬30 (wtDEN-4 on day 4 versus 2A⌬30 on day 5; unpaired t-test; df ϭ 4, P ϭ 0.003).
Oral infectious dose 50 in Ae. aegypti. The OID 50 of wt DEN-4 and 2A⌬30 was determined by allowing Ae. aegypti mosquitoes to feed on an artificial blood meal containing serial 10-fold dilutions of virus. 2A⌬30 was restricted both in its ability to infect the midgut and to cause a disseminated infection relative to wtDEN-4 ( Table 1 ). The calculated OID 50 for total infection was 10 3.5 plaque-forming units (PFU) for wtDEN-4 versus 10 4.0 PFU for 2A⌬30, a difference that is small but statistically significant. Both viruses showed similar intensity of staining in the midgut, suggesting that comparable levels of replication occurred at this site. In comparison, the calculated OID 50 for disseminated infection was 10 4.0 PFU for wtDEN-4 versus Ն 10 4.8 PFU for 2A⌬30, a difference that is statistically significant ( Table 1) . The OID 50 value for 2A⌬30 was estimated by assuming that a 10-fold more concentrated virus stock would have infected 100% of 50 mosquitoes. Consequently, the value of Ն 10 4.8 PFU is quite conservative and the actual OID 50 for disseminated infection is probably much larger.
Mosquito infectious dose 50 by the intrathoracic route in T. splendens. We next addressed the question of whether the 2A⌬30 vaccine candidate was specifically restricted in replication in tissues other than the midgut or whether it was more sensitive than its wild type parent to the midgut escape barrier. To address this, the attenuated and wild type DEN-4 viruses were inoculated intrathoracically into T. splendens, permitting experimental bypass of the midgut escape barrier, and the MID 50 was determined by scoring the presence of viral antigen in head tissues. Both wtDEN-4 and 2A⌬30 exhibited similar levels of infectivity when administered by the intrathoracic route in T. splendens (Table 2) , and both viruses showed similar intensity of staining in the head tissue. The calculated MID 50 for the wtDEN-4 in Toxorhynchites was 10 2.7 PFU and that for 2A⌬30 was 10 2.5 PFU. The MID 50 for both viruses was approximately 10-fold lower for intrathoracic inoculation of T. splendens compared with oral infection of Ae. aegypti. This difference was not unexpected, given that mosquitoes tend to be more sensitive to direct inoculation of virus compared with oral infection. 25 A logistic regression on the percentage of infections caused by intrathoracic inoculation with the first four dilutions of each virus indicates no significant difference between wtDEN-4 and 2A⌬30 (n ϭ 74; P Ͼ 0.9). These findings demonstrate that similar levels of replication of the attenuated and wild type virus occur in head tissues and indicate that 2A⌬30 is more sensitive than its wild type parent to the midgut escape barrier.
Lack of transmission of the 2A⌬30 vaccine candidate from vaccinees to mosquitoes. To assess the potential for transmission of 2A⌬30 via a natural route, Ae. albopictus were allowed to feed on the vacinees during the period of expected peak viremia (days 7, 8, and 9 post-vaccination). Of the 352 mosquitoes fed on vaccinees, none contained dengue virus antigen in either the midgut or the head (Table  3) . These results indicate that 2A⌬30 was very poorly, if at all, transmissible from infected vaccinees to mosquitoes.
We measured viremia during this period using both in vitro and in vivo methods. First, the quantity of virus present in volunteer sera was determined in vitro by plaque titration assay in Vero cells and also by amplification on Vero cell monolayer cultures. 18 Nine of the ten vaccinees had detectable viremia on at least one day of the entire 14-day study, but only five had detectable viremia on days 7, 8, and 9 (Table 3) . To compare the sensitivity of the plaque assay with mosquito inoculation, which has been reported to be the most sensitive assay for detection of virus in blood, 23, 26 an in vivo assay was performed in which groups of T. splendens were inoculated with serum collected on day 9 from each vaccinee (Table 3) . Both serum specimens containing virus that produced plaques in Vero cells on day 9 also infected one or more of the inoculated mosquitoes. Of the eight serum samples that did not produce plaques, serum from vaccinee #7 infected a single mosquito. It should be noted that serum from vaccinee #7 produced plaques on day 10 post-vaccination. Thus, we concluded that plaque assay was as sensitive as mosquito inoculation for detecting viremia in vaccinees inoculated with 2A⌬30, and consequently sera from days 7 and 8 were not similarly tested by mosquito inoculation.
DISCUSSION
The dengue virus vaccine candidate 2A⌬30 was previously found to be safe and immunogenic in vaccinated volunteers 18 and was found in the present study to exhibit limited potential for transmission by mosquitoes. Transmissibility of a live attenuated virus vaccine by mosquitoes is unacceptable because it places unvaccinated individuals at risk of infection, either by the original vaccine candidate or by more virulent derivatives created by the loss of attenuating mutations. 8, 9 In the current study, 2A⌬30 demonstrated a reduced capability for infecting the midgut and for causing a disseminated infection in mosquitoes infected by artificial membrane feeding. Furthermore, 2A⌬30 was not transmitted from vaccinees to mosquitoes that were allowed to feed on the vaccinees during a period of viremia.
Both 2A⌬30 and its wild type parent virus each replicated efficiently in both mosquito cell and simian cell cultures. The peak titer of the wild type parent was approximately 10-fold greater than that of 2A⌬30 in mosquito cells but was nearly identical in Vero cells. Thus, the attenuating effect of the 30-nucleotide deletion mutation, manifest in monkeys, humans, and mosquitoes, was reflected in a slightly impaired ability to replicate in vitro in mosquito cells but not in simian cells. The robust growth of 2A⌬30 candidate in Vero cells is encouraging because this cell line is a potential substrate for vaccine manufacture. The replication of another candidate vaccine virus, the PDK-53 DEN-2 vaccine candidate, was restricted more than 1,000-fold in C6/36 cells. 12 This phenotype was specified by one mutation in its 5Ј untranslated region and one mutation in its NS-1 protein. 27 The PDK-53 vaccine candidate was also restricted in its replication in mosquitoes, indicating that its decreased replication in C6/36 cells reflects its restricted replication in mosquitoes. A similar pattern was seen in this study, although the restriction in replication in mosquito cells was of a much smaller magnitude.
The infectivity of 2A⌬30 in mosquitoes was also examined. Infection of mosquitoes by feeding on an artificial blood meal containing dengue virus permits a determination of whether the virus can efficiently replicate in the midgut and spread to the salivary glands. After feeding on an artificial blood meal, the OID 50 for midgut infection of Ae. aegypti was slightly but significantly higher for 2A⌬30 than for wtDEN-4. Nonetheless, the relatively high level of infectivity of 2A⌬30 for the mosquito midgut differs from that of many previous vaccine candidates, which are poorly infectious for the midgut. [27] [28] [29] [30] However, the OID 50 necessary for a disseminated infection was approximately 10-fold higher for 2A⌬30 than for its parent virus, indicating that 2A⌬30 is restricted in its ability to cross the midgut barrier. This interpretation was strengthened by the results from intrathoracic inoculation of T. splendens with the two viruses. Intrathoracic inoculation circumvents the midgut barrier by placing virus directly into the hemolymph of the mosquito, and only infection of the head is evaluated. Thus, if the failure to escape the midgut barrier is responsible for the low rate of dissemination of 2A⌬30, the vaccine candidate and its parent should show a similar level of head infection after intrathoracic inoculation. The MID 50 for 2A⌬30 in T. splendens was almost identical to that of wtDEN-4, and the extent and intensity of the staining in both groups was also comparable. Thus, the 30-nucleotide deletion in the 3Ј untranslated region of 2A⌬30 rendered the vaccine candidate more sensitive than its wild type parent to the midgut escape barrier. 31 The DEN-1 PDK-13 vaccine candidate has a similar phenotype, since it is restricted in dissemination but not in midgut infection. 32 Virus present in a blood meal from a viremic human may be more infectious for mosquitoes than virus present in an artificial blood meal. 33 In addition, a previous study indicated that DEN-2 PR-159 S1 vaccine candidate could spread from an infected vaccinee to mosquitoes, although at a very low rate, even from a vaccinee with a low level of viremia. 30 It was therefore necessary to evaluate whether 2A⌬30 could infect Ae. albopictus that fed on volunteers who had been infected with 2A⌬30. It was found that none of 352 mosquitoes that fed on 10 vaccinees became infected. It should be noted that only one strain of Ae. albopictus was used in this study, and susceptibility to infection varies among species of mosquito and among strains within a species. 25 However, this species was susceptible to infection via an artificial blood meal.
The very large quantity of dengue virus found in human blood during a natural infection (more than 10 8.0 infectious units/ml 4, 34 ) facilitates transmission of the virus to mosquitoes. Conversely, the very low titer of virus in recipients of attenuated dengue virus vaccines should thwart transmission of the vaccine virus. The level of viremia in the vaccinees who received 2A⌬30 was extremely low, and virus could not be detected in most volunteers on most days using a plaque assay or inoculation of T. splendens. Estimates of the minimum quantity of virus present in human blood necessary for successful transmission to a mosquito generally vary between approximately 10 4 and 10 6 infectious units of virus/ ml. 33 Since the 2A⌬30 vaccine candidate readily infected the midgut of the mosquito during experimental feeding, the reduced transmissibility of 2A⌬30 from vaccinees to mosquitoes was predominantly a function of the very low titer of virus in the blood of the vaccinees.
Wild type DEN-4 may be less virulent than the other three wild type dengue serotypes. 35 Thus, two factors may contribute to the attenuation of 2A⌬30 in vaccinees: the wt DEN-4 sequence and the ⌬30 deletion. The relative contribution of the DEN-4 backbone to the attenuation of 2A⌬30 in vaccinees remains undefined. However, since the replication of 2A⌬30 in vaccinees is below that required for transmission, the ⌬30 mutation clearly contributes to attenuation of 2A⌬30 for humans. Moreover, 2A⌬30 possesses an additional safeguard against transmission. Even if it should replicate to a titer sufficient for transmission, the decreased ability of this vaccine candidate to infect the midgut and to escape from the midgut barrier, both observed in the present study, would further decrease its likelihood of being transmitted to a new human host. These observations suggest that the likelihood of vector transmission of 2A⌬30 from vaccinated individuals is extremely low.
Development of chimeric viruses using the 2A⌬30 nonstructural genes and the DEN-1, DEN-2, and DEN-3 structural genes are currently in progress. The 30-nucleotide deletion in the 3Ј-untranslated region of 2A⌬30 will be common to each of these viruses. Therefore, it is possible that we will see similar levels of attenuation and low levels of viremia for each of the four viruses with minimal interference when these viruses are combined in a tetravalent vaccine. 18 Additionally, we predict that the chimeric viruses will show a pattern of midgut restriction similar to that of 2A⌬30. However, because dengue virus serotypes differ in their mosquito infectivity, the experiments presented here will need to be repeated in the future for each of the chimeric viruses as well as for the tetravalent vaccine.
